← Leaderboards
Craig Lewis Duvall
University Of Washington
$15,130,944
Attributed
$22,251,241
Total exposure
18
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.4M · FY2008–25$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$22,251,241 · 18
By mechanism
R01$19,056,252 · 9
R21$2,285,903 · 6
R33$489,644 · 1
T32$336,630 · 1
F32$82,812 · 1
Top collaborators
- Rebecca Sara Cook15 shared
- Dana M Brantley-Sieders9 shared
- Md Jashim Uddin7 shared
- Kasey C Vickers7 shared
- Mukesh Kumar Gupta5 shared
- Ethan Lippmann3 shared
- Julie A Sterling3 shared
- Jonathan Matthew Brunger2 shared
Most similar at University Of Washington
Same institution · by research overlap
- Jennifer Marie Specht$1,851,288
- Antonios G. Mikos$14,067,698
- Maryam Ganjehzadeh Rohani$110,560
- Karl F Bohringer$4,001,383
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoPharmaceutical PreparationsTechnologyPolymersCellsFormulationDesignChemistryBiomedical EngineeringBiologicalSiteDrug Delivery SystemsBaseNanoparticleDrug KineticsLeadSmall Interfering RnaGene SilencingDoseTissuesPhenotypeTreatment EfficacySuccessIn Vitro
Grant awards (60)
Targeting brain myeloid cells with siRNA-lipid conjugates for treatment of Alzheimer's disease$787,103
R01 · FY2025 · AG
Next Gen Targeted nanoparticles for Inhibiting Gli2 in Bone Metastatic Tumors$648,024
R01 · FY2025 · CA
Bioresorbable Polythioketal Urethane Wound Dressings$563,442
R01 · FY2025 · EB · contact PI
In Situ Albumin Binding siRNAs for Triple Negative Breast Cancer Tumor Penetration and Molecularly Targeted Therapy$550,518
R01 · FY2025 · CA · contact PI
Carrier Free siRNA Conjugates as Disease Modifying Osteoarthritis Drugs$527,466
R01 · FY2025 · AR · contact PI
Drug Coated Balloon Peptide Delivery to Block Post-angioplasty Restenosis in PAD$489,644
R33 · FY2025 · HL · contact PI
Tissue Adhesive RNA Interference Nanoparticles to Block Progression of Posttraumatic and Spontaneous Osteoarthritis.$478,366
R01 · FY2025 · AR · contact PI
Integrated Training in Bone Biology, Biomechanics, and Regeneration (IT3BR)$336,630
T32 · FY2025 · AR
Next Gen Targeted nanoparticles for Inhibiting Gli2 in Bone Metastatic Tumors$616,177
R01 · FY2024 · CA
Carrier Free siRNA Conjugates as Disease Modifying Osteoarthritis Drugs$595,117
R01 · FY2024 · AR · contact PI
Bioresorbable Polythioketal Urethane Wound Dressings$570,185
R01 · FY2024 · EB · contact PI
In Situ Albumin Binding siRNAs for Triple Negative Breast Cancer Tumor Penetration and Molecularly Targeted Therapy$522,993
R01 · FY2024 · CA · contact PI
Tissue Adhesive RNA Interference Nanoparticles to Block Progression of Posttraumatic and Spontaneous Osteoarthritis.$492,510
R01 · FY2024 · AR · contact PI
Next Gen Targeted nanoparticles for Inhibiting Gli2 in Bone Metastatic Tumors$667,924
R01 · FY2023 · CA
Bioresorbable Polythioketal Urethane Wound Dressings$583,452
R01 · FY2023 · EB · contact PI
In Situ Albumin Binding siRNAs for Triple Negative Breast Cancer Tumor Penetration and Molecularly Targeted Therapy$555,637
R01 · FY2023 · CA · contact PI
Tissue Adhesive RNA Interference Nanoparticles to Block Progression of Posttraumatic and Spontaneous Osteoarthritis.$543,150
R01 · FY2023 · AR · contact PI
Hybrid Synthetic and Biologic Shear Thinning Hydrogels for Diabetic Wound Healing$475,355
R01 · FY2023 · EB · contact PI
Albumin hitchhiking siRNAs for gene targeting in aged brain$190,001
R21 · FY2023 · AG
In Situ Albumin Binding siRNAs for Triple Negative Breast Cancer Tumor Penetration and Molecularly Targeted Therapy$117,567
R01 · FY2023 · CA · contact PI
Tissue Adhesive RNA Interference Nanoparticles to Block Progression of Posttraumatic and Spontaneous Osteoarthritis.$622,051
R01 · FY2022 · AR · contact PI
In Situ Albumin Binding siRNAs for Triple Negative Breast Cancer Tumor Penetration and Molecularly Targeted Therapy$553,948
R01 · FY2022 · CA · contact PI
Hybrid Synthetic and Biologic Shear Thinning Hydrogels for Diabetic Wound Healing$475,243
R01 · FY2022 · EB · contact PI
NextGen RNAi Delivery to Breast Tumors for Selective mTORC2 Blockade$441,312
R01 · FY2022 · CA · contact PI
Albumin hitchhiking siRNAs for gene targeting in aged brain$229,785
R21 · FY2022 · AG
Albumin Binding siRNAs for Systemic Treatment of Multi-Joint Osteoarthritis$204,011
R21 · FY2022 · AR · contact PI
In situ Cell Engineering for On-demand TIMP Expression in Osteoarthritis$156,915
R21 · FY2022 · AR · contact PI
In Situ Albumin Binding siRNAs for Triple Negative Breast Cancer Tumor Penetration and Molecularly Targeted Therapy$117,567
R01 · FY2022 · CA · contact PI
NextGen RNAi Delivery to Breast Tumors for Selective mTORC2 Blockade$72,819
R01 · FY2022 · CA · contact PI
In Situ Albumin Binding siRNAs for Triple Negative Breast Cancer Tumor Penetration and Molecularly Targeted Therapy$617,228
R01 · FY2021 · CA · contact PI
NextGen RNAi Delivery to Breast Tumors for Selective mTORC2 Blockade$450,319
R01 · FY2021 · CA · contact PI
Albumin Binding siRNAs for Systemic Treatment of Multi-Joint Osteoarthritis$170,194
R21 · FY2021 · AR · contact PI
In situ Cell Engineering for On-demand TIMP Expression in Osteoarthritis$118,875
R21 · FY2021 · AR · contact PI
Hybrid Synthetic and Biologic Shear Thinning Hydrogels for Diabetic Wound Healing$75,004
R01 · FY2021 · EB · contact PI
NextGen RNAi Delivery to Breast Tumors for Selective mTORC2 Blockade$74,306
R01 · FY2021 · CA · contact PI
Hybrid Synthetic and Biologic Shear Thinning Hydrogels for Diabetic Wound Healing$474,007
R01 · FY2020 · EB · contact PI
NextGen RNAi Delivery to Breast Tumors for Selective mTORC2 Blockade$450,319
R01 · FY2020 · CA · contact PI
NextGen RNAi Delivery to Breast Tumors for Selective mTORC2 Blockade$74,113
R01 · FY2020 · CA · contact PI
MK2 Inhibitory Nanoplexes to Enhance Long-Term Vascular Graft Patency$62,970
R01 · FY2020 · HL · contact PI
MK2 Inhibitory Nanoplexes to Enhance Long-Term Vascular Graft Patency$594,486
R01 · FY2019 · HL · contact PI
Hybrid Synthetic and Biologic Shear Thinning Hydrogels for Diabetic Wound Healing$488,507
R01 · FY2019 · EB · contact PI
NextGen RNAi Delivery to Breast Tumors for Selective mTORC2 Blockade$436,809
R01 · FY2019 · CA · contact PI
MK2 Inhibitory Nanoplexes to Enhance Long-Term Vascular Graft Patency$595,700
R01 · FY2018 · HL · contact PI
NextGen RNAi Delivery to Breast Tumors for Selective mTORC2 Blockade$464,569
R01 · FY2018 · CA · contact PI
Substrate Mediated siRNA Delivery from Scaffolds to Promote Wound Repair$343,669
R01 · FY2018 · EB · contact PI
MK2 Inhibitory Nanoplexes to Enhance Long-Term Vascular Graft Patency$522,841
R01 · FY2017 · HL · contact PI
Substrate Mediated siRNA Delivery from Scaffolds to Promote Wound Repair$343,669
R01 · FY2017 · EB · contact PI
MK2 Inhibitory Nanoplexes to Enhance Long-Term Vascular Graft Patency$57,588
R01 · FY2017 · HL · contact PI
Substrate Mediated siRNA Delivery from Scaffolds to Promote Wound Repair$343,856
R01 · FY2016 · EB · contact PI
MK2 Inhibitory Nanoplexes to Enhance Long-Term Vascular Graft Patency$326,985
R01 · FY2016 · HL · contact PI
Substrate Mediated siRNA Delivery from Scaffolds to Promote Wound Repair$337,160
R01 · FY2015 · EB · contact PI
Substrate Mediated siRNA Delivery from Scaffolds to Promote Wound Repair$344,221
R01 · FY2014 · EB · contact PI
Quantitative In Vivo Optical Imaging of Vascular Response to Hind Limb Ischemia$212,106
R21 · FY2013 · HL · contact PI
Injectable Scaffold for Efficient, Tunable siRNA Delivery to Skin Wounds$228,232
R21 · FY2012 · EB · contact PI
Smart Polymer Based MK2 Inhibitor to Suppress Vascular Graft Intimal Hyperplasia$220,536
R21 · FY2012 · HL · contact PI
Quantitative In Vivo Optical Imaging of Vascular Response to Hind Limb Ischemia$183,800
R21 · FY2012 · HL · contact PI
Injectable Scaffold for Efficient, Tunable siRNA Delivery to Skin Wounds$189,400
R21 · FY2011 · EB · contact PI
Smart Polymer Based MK2 Inhibitor to Suppress Vascular Graft Intimal Hyperplasia$182,048
R21 · FY2011 · HL · contact PI
Intracellular Peptide Delivery for Targeted Destruction of Cancer$35,986
F32 · FY2009 · CA · contact PI
Intracellular Peptide Delivery for Targeted Destruction of Cancer$46,826
F32 · FY2008 · CA · contact PI